|
1
|
Hezel AF, Kimmelman AC, Stanger BZ,
Bardeesy N and Depinho RA: Genetics and biology of pancreatic
ductal adenocarcinoma. Genes Dev. 20:1218–1249. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hishinuma S, Ogata Y, Tomikawa M, Ozawa I,
Hirabayashi K and Igarashi S: Patterns of recurrence after curative
resection of pancreatic cancer, based on autopsy findings. J
Gastrointest Surg. 10:511–518. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Iacobuzio-Donahue CA, Fu B, Yachida S, Luo
M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P,
et al: DPC4 gene status of the primary carcinoma correlates with
patterns of failure in patients with pancreatic cancer. J Clin
Oncol. 27:1806–1813. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Philip PA and Lutz MP: Targeting epidermal
growth factor receptor-related signaling pathways in pancreatic
cancer. Pancreas. 44:1046–1052. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tobita K, Kijima H, Dowaki S, Kashiwagi H,
Ohtani Y, Oida Y, Yamazaki H, Nakamura M, Ueyama Y, Tanaka M, et
al: Epidermal growth factor receptor expression in human pancreatic
cancer: Significance for liver metastasis. Int J Mol Med.
11:305–309. 2003.PubMed/NCBI
|
|
7
|
Bloomston M, Bhardwaj A, Ellison EC and
Frankel WL: Epidermal growth factor receptor expression in
pancreatic carcinoma using tissue microarray technique. Dig Surg.
23:74–79. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mahipal A, Mcdonald MJ, Witkiewicz A and
Carr BI: Cell membrane and cytoplasmic epidermal growth factor
receptor expression in pancreatic ductal adenocarcinoma. Med Oncol.
29:134–139. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang JP, Wu CY, Yeh YC, Shyr YM, Wu YY,
Kuo CY, Hung YP, Chen MH, Lee WP, Luo JC, et al: Erlotinib is
effective in pancreatic cancer with epidermal growth factor
receptor mutations: A randomized, open-label, prospective trial.
Oncotarget. 6:18162–18173. 2015.PubMed/NCBI
|
|
11
|
Herman JM, Fan KY, Wild AT, Hacker-Prietz
A, Wood LD, Blackford AL, Ellsworth S, Zheng L, Le DT, De
Jesus-Acosta A, et al: Phase 2 study of erlotinib combined with
adjuvant chemoradiation and chemotherapy in patients with
resectable pancreatic cancer. Int J Radiat Oncol Biol Phys.
86:678–685. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sinn M, Bahra M, Liersch T, Gellert K,
Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau
BM, et al: CONKO-005: Adjuvant chemotherapy with gemcitabine plus
erlotinib versus gemcitabine alone in patients after R0 resection
of pancreatic cancer: A multicenter randomized phase III trial. J
Clin Oncol. 35:3330–3337. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ardito CM, Grüner BM, Takeuchi KK,
Lubeseder-Martellato C, Teichmann N, Mazur PK, Delgiorno KE,
Carpenter ES, Halbrook CJ, Hall JC, et al: EGF receptor is required
for KRAS-induced pancreatic tumorigenesis. Cancer Cell. 22:304–317.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Navas C, Hernández-Porras I, Schuhmacher
AJ, Sibilia M, Guerra C and Barbacid M: EGF receptor signaling is
essential for k-ras oncogene-driven pancreatic ductal
adenocarcinoma. Cancer Cell. 22:318–330. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Molina MA, Sitja-Arnau M, Lemoine MG,
Frazier ML and Sinicrope FA: Increased cyclooxygenase-2 expression
in human pancreatic carcinomas and cell lines: growth inhibition by
nonsteroidal anti-inflammatory drugs. Cancer Res. 59:4356–4362.
1999.PubMed/NCBI
|
|
16
|
Kokawa A, Kondo H, Gotoda T, Ono H, Saito
D, Nakadaira S, Kosuge T and Yoshida S: Increased expression of
cyclooxygenase-2 in human pancreatic neoplasms and potential for
chemoprevention by cyclooxygenase inhibitors. Cancer. 91:333–338.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Juuti A, Louhimo J, Nordling S, Ristimäki
A and Haglund C: Cyclooxygenase-2 expression correlates with poor
prognosis in pancreatic cancer. J Clin Pathol. 59:382–386. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Matsubayashi H, Infante JR, Winter J,
Klein AP, Schulick R, Hruban R, Visvanathan K and Goggins M: Tumor
COX-2 expression and prognosis of patients with resectable
pancreatic cancer. Cancer Biol Ther. 6:1569–1575. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Richards NG, Rittenhouse DW, Freydin B,
Cozzitorto JA, Grenda D, Rui H, Gonye G, Kennedy EP, Yeo CJ, Brody
JR and Witkiewicz AK: HuR status is a powerful marker for prognosis
and response to gemcitabine-based chemotherapy for resected
pancreatic ductal adenocarcinoma patients. Ann Surg. 252:499–506.
2010.PubMed/NCBI
|
|
20
|
Koshiba T, Hosotani R, Miyamoto Y, Wada M,
Lee JU, Fujimoto K, Tsuji S, Nakajima S, Doi R and Imamura M:
Immunohistochemical analysis of cyclooxygenase-2 expression in
pancreatic tumors. Int J Pancreatol. 26:69–76. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Okami J, Yamamoto H, Fujiwara Y, Tsujie M,
Kondo M, Noura S, Oshima S, Nagano H, Dono K, Umeshita K, et al:
Overexpression of cyclooxygenase-2 in carcinoma of the pancreas.
Clin Cancer Res. 5:2018–2024. 1999.PubMed/NCBI
|
|
22
|
Merati K, said Siadaty M, Andea A, Sarkar
F, Ben-Josef E, Mohammad R, Philip P, Shields AF, Vaitkevicius V,
Grignon DJ and Adsay NV: Expression of inflammatory modulator COX-2
in pancreatic ductal adenocarcinoma and its relationship to
pathologic and clinical parameters. Am J Clin Oncol. 24:447–452.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lipton A, Campbell-Baird C, Witters L,
Harvey H and Ali S: Phase II trial of gemcitabine, irinotecan, and
celecoxib in patients with advanced pancreatic cancer. J Clin
Gastroenterol. 44:286–288. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kirane A, Toombs JE, Ostapoff K, Carbon
JG, Zaknoen S, Braunfeld J, Schwarz RE, Burrows FJ and Brekken RA:
Apricoxib, a novel inhibitor of COX-2, markedly improves standard
therapy response in molecularly defined models of pancreatic
cancer. Clin Cancer Res. 18:5031–5042. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hill R, Li Y, Tran LM, Dry S, Calvopina
JH, Garcia A, Kim C, Wang Y, Donahue TR, Herschman HR and Wu H:
Cell intrinsic role of COX-2 in pancreatic cancer development. Mol
Cancer Ther. 11:2127–2137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang CC and Chang KW: Eicosanoids and
HB-EGF/EGFR in cancer. Cancer Metastasis Rev. 23–Jun;2018.(Epub
ahead of print). View Article : Google Scholar
|
|
27
|
Wang D, Xia D and Dubois RN: The crosstalk
of PTGS2 and EGF signaling pathways in colorectal cancer. Cancers
(Basel). 3:3894–3908. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Axelsson H, Lönnroth C, Andersson M and
Lundholm K: Mechanisms behind COX-1 and COX-2 inhibition of tumor
growth in vivo. Int J Oncol. 37:1143–1152. 2010.PubMed/NCBI
|
|
29
|
Lönnroth C, Andersson M, Asting AG,
Nordgren S and Lundholm K: Preoperative low dose NSAID treatment
influences the genes for stemness, growth, invasion and metastasis
in colorectal cancer. Int J Oncol. 45:2208–2220. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Valsecchi ME, McDonald M, Brody JR, Hyslop
T, Freydin B, Yeo CJ, Solomides C, Peiper SC and Witkiewicz AK:
Epidermal growth factor receptor and insulinlike growth factor 1
receptor expression predict poor survival in pancreatic ductal
adenocarcinoma. Cancer. 118:3484–3493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lim JE, Chien MW and Earle CC: Prognostic
factors following curative resection for pancreatic adenocarcinoma:
A population-based, linked database analysis of 396 patients. Ann
Surg. 237:74–85. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ueda S, Ogata S, Tsuda H, Kawarabayashi N,
Kimura M, Sugiura Y, Tamai S, Matsubara O, Hatsuse K and Mochizuki
H: The correlation between cytoplasmic overexpression of epidermal
growth factor receptor and tumor aggressiveness: Poor prognosis in
patients with pancreatic ductal adenocarcinoma. Pancreas. 29:e1–e8.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Perini MV, Montagnini AL, Coudry R,
Patzina R, Penteado S, Abdo EE, Diniz A, Jukemura J and da Cunha
JE: Prognostic significance of epidermal growth factor receptor
overexpression in pancreas cancer and nodal metastasis. ANZ J Surg.
85:174–178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Smeenk HG, Erdmann J, van Dekken H, van
Marion R, Hop WC, Jeekel J and van Eijck CH: Long-term survival
after radical resection for pancreatic head and ampullary cancer: A
potential role for the EGF-R. Dig Surg. 24:38–45. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Park SJ, Gu MJ, Lee DS, Yun SS, Kim HJ and
Choi JH: EGFR expression in pancreatic intraepithelial neoplasia
and ductal adenocarcinoma. Int J Clin Exp Pathol. 8:8298–8304.
2015.PubMed/NCBI
|
|
36
|
Wang L, Wu H, Wang L, Lu J, Duan H, Liu X
and Liang Z: Expression of amphiregulin predicts poor outcome in
patients with pancreatic ductal adenocarcinoma. Diagn Pathol.
11:602016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Almoguera C, Shibata D, Forrester K,
Martin J, Arnheim N and Perucho M: Most human carcinomas of the
exocrine pancreas contain mutant c-K-ras genes. Cell. 53:549–554.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yamanaka Y, Friess H, Kobrin MS, Buchler
M, Beger HG and Korc M: Coexpression of epidermal growth factor
receptor and ligands in human pancreatic cancer is associated with
enhanced tumor aggressiveness. Anticancer Res. 13:565–569.
1993.PubMed/NCBI
|
|
39
|
Asting AG, Farivar A, Iresjö BM, Svensson
H, Gustavsson B and Lundholm K: EGF receptor and COX-1/COX-2 enzyme
proteins as related to corresponding mRNAs in human per-operative
biopsies of colorectal cancer. BMC Cancer. 13:5112013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hu H, Han T, Zhuo M, Wu LL, Yuan C, Wu L,
Lei W, Jiao F and Wang LW: Elevated COX-2 expression promotes
angiogenesis through EGFR/p38-MAPK/Sp1-dependent signalling in
pancreatic cancer. Sci Rep. 7:4702017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lozano-Leon A, Perez-Quintela BV,
Iglesias-García J, Lariño-Noia J, Varo E, Forteza J and
Domínguez-Muñoz JE: Ductal adenocarcinoma of the pancreas:
Expression of growth factor receptors, oncogenes and suppressor
genes, and their relationship to pathological features, staging and
survival. Oncol Lett. 2:161–166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Khouja MH, Baekelandt M, Sarab A, Nesland
JM and Holm R: Limitations of tissue microarrays compared with
whole tissue sections in survival analysis. Oncol Lett. 1:827–831.
2010. View Article : Google Scholar : PubMed/NCBI
|
